Core Viewpoint - Kenvue Inc. shares experienced a decline of over 10% following a report indicating a potential link between the use of its pain medication Tylenol by pregnant women and autism, as suggested by Health and Human Services Secretary Robert F. Kennedy Jr. [1] Group 1 - Kenvue's stock fell more than 10% on Friday due to concerns over a forthcoming report linking Tylenol to autism [1] - The report is expected to be released this month and may have significant implications for Kenvue [1] - The Wall Street Journal highlighted that the report could draw a connection between Tylenol use in pregnant women and autism [1] Group 2 - The same report will also propose that a medicine derived from folate could be effective in treating symptoms of autism in some individuals [2]